Hepatitis C Patients Often Denied Live-Saving Drugs

Hepatitis C Patients Often Denied Live-Saving Drugs

June 2018

New research led by Vincent Lo Re III, MD, MSCE, shows that people with hepatitis C still frequently meet with insurance denials for once-a-day pills that became available in the United States in 2014 and have a 95 percent cure rate, with few side effects. Read more.

Share this Content

About Us

To understand health and disease today, we need new thinking and novel science —the kind  we create when multiple disciplines work together from the ground up. That is why this department has put forward a bold vision in population-health science: a single academic home for biostatistics, epidemiology and informatics. LEARN MORE ABOUT US

© 2021 Trustees of the University of Pennsylvania. All rights reserved. | Disclaimer

Follow Us